A practical reference on bremelanotide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
| Property | Value | Notes |
|---|---|---|
| Primary receptor targets | MC4R and MC1R | Agonist activity; MC3R and MC5R weaker |
| Route studied in trials | Subcutaneous injection | Intranasal form was not approved |
| Elimination half-life | Approximately 2–3 hours | Short relative to the dosing interval |
| Common analytical method | Liquid chromatography–tandem mass spectrometry | Used for peptide quantification in plasma |
| Reported adverse events | Nausea, flushing, headache | Transient blood pressure rise also noted |
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
== External links == International Chemical Safety Card 1104 SIDS Initial Assessment Report for 1,4-Butanediol from the Organisation for Economic Co-operation and Development (OECD) Record in the Household Products Database of NLM
=== Pulmonary function testing === Most patients with suspected ILD are likely to undergo complete pulmonary function testing. These tests are useful in diagnosis and determining severity of the disease. Although there is large diversity in interstitial lung disease, most follow a restrictive pattern. Restrictive defects are defined by decreased TLC (total lung capacity), RV (residual volume), FVC (forced vital capacity) and FEV1 (forced expiratory volume in one second). As both FVC and FEV1 are reduced, the FVC to FEV1 ratio remains normal or is increased. As disease progression increases and the lungs become stiffer lung volumes will continue to decrease; lower TLC, RV, FVC and FEV1 scores are associated with a more severe disease progression and poorer prognosis.
A soldier going to battle on Pervitin usually found himself unable to perform effectively for the next day or two. Suffering from a drug hangover and looking more like a zombie than a great warrior, he had to recover from the side effects. Some soldiers turned violent, committing war crimes against civilians; others attacked their own officers. At the end of the war, it was used as part of a new drug: D-IX. Obetrol, patented by Obetrol Pharmaceuticals in the 1950s and indicated for treatment of obesity, was one of the first brands of pharmaceutical methamphetamine products. Because of the psychological and stimulant effects of methamphetamine, Obetrol became a popular diet pill in the United States in the 1950s and 1960s. Eventually, as the addictive properties of the drug became known, governments began to strictly regulate the production and distribution of methamphetamine. For example, during the early 1970s in the United States, methamphetamine became a schedule II controlled substance under the Controlled Substances Act. As of January 2013, the Desoxyn trademark had been sold to Italian pharmaceutical company Recordati.
8 July An infantry battalion numbering 814 men from the US Army's 9th Infantry Division, the first of 25,000 American troops to be withdrawn from South Vietnam, arrived at McChord Air Force Base at 18:30 in a C-141 transport plane.
=== Congenital heart defects === In some cases, critical congenital heart defects (CCHD) are not identified by prenatal ultrasound or postnatal physical examination. Pulse oximetry has been recently added as a bedside screening test for CCHD at 24 to 48 hours after birth. However, not all heart problems can be detected by this method, which relies only on blood oxygen levels. When a baby tests positive, urgent subsequent examination, such as echocardiography, is undergone to determine the cause of low oxygen levels. Babies diagnosed with CCHD are then seen by cardiologists.
Sources: en.wikipedia.org
== Medical uses == Second generation cephalosporins are more effective in treating Gram-negative bacilli compared to first generation cephalosporins, which have a greater coverage for Gram-positive cocci. Also, it has been reported that cefuroxime is resistant to hydrolysis by β-lactamases produced by Gram-negative bacteria. Some medical uses are:
=== August === 6 August – Tom O'Connor, journalist, author, senior citizens' advocate and local politician, president of Grey Power (2016–2018), Waimate District Councillor (since 2013) (born 1944). 8 August Judy Bailey, pianist, composer, jazz musician and educator (Sydney Conservatorium of Music), and television presenter (Play School) (born 1935). Peter Lester, sailor, sailing coach and commentator, OK dinghy world champion (1977), Admiral's Cup winner (1987, 1993) (born 1954). 10 August – Patrick Waddington, Russian linguist, literary critic and historian (Victoria University of Wellington) (born 1934). 13 August – Grant Tavinor, philosopher (Lincoln University) (born c. 1973). 15 August – John Rowan, lawyer, King's Counsel (since 1997) (born 1944). 16 August – Janet Grieve, biological oceanographer (New Zealand Oceanographic Institute, NIWA), New Zealand Association of Scientists president (1998–2000), World Association of Copepodologists president (2008–2011) (born 1940). 17 August – John Bartley, cinematographer (Lost, The X Files, The Chronicles of Riddick), Emmy Award (1996) (born 1947). 18 August Lloyd Ashby, rugby union player (Southland, national team) (born 1931). Lindsay Sparks, cricketer (Central Districts, Auckland) and rugby union player (Marlborough) (born 1944). 19 August – Tony Smith, legal scholar (University of Reading, University of Cambridge, Victoria University of Wellington) (born 1947). 21 August Evelyn Attwood, tennis player (born 1924). Keith Nelson, rugby union player (Otago, Auckland, national team) and dentist (born 1938).
=== Cation exchange === Cation exchange sorbents are derivatized with functional groups that interact and retain positively charged cations, such as bases. Strong cation exchange sorbents contain aliphatic sulfonic acid groups that are always negatively charged in aqueous solution, and weak cation exchange sorbents contain aliphatic carboxylic acids, which are charged when the pH is above about 5. Strong cation exchange sorbents are useful because any strongly basic impurities in the sample will bind to the sorbent and usually will not be eluted with the analyte of interest; to recover a strong base a weak cation exchange cartridge should be used. To elute the analyte from either the strong or weak sorbent, the stationary phase is washed with a solvent that neutralizes ionic interaction between the analyte and the stationary phase.
== R == r-selection – radiobiology – receptor (biochemistry) – receptor (immunology) – recombination – Red Queen – redox reaction – redox system – reduction – reflex – Renal corpuscle – repeats – replication bubble – repressor – reproduction – reproductive system – respiration (physiology) – restriction enzyme – retrovirus – reverse genetics – RFLP – Rh blood group system – ribosome – RNA – RNA virus – Robert Koch – root – rough ER – RuBP – Rudolf Steiner –
Net sales for fiscal 2002 were $182 million in spite of a shaky economic climate. Bowman retired as chairman of the board in 2005, but continued to serve on the board of directors. Net sales for fiscal 2005 were $279.3 million, and by 2007 had reached $327.3 million. In 2010, Dionex was acquired by Thermo Fisher Scientific for $2.1 billion.
Sources: en.wikipedia.org
=== Traditional === Rotheca myricoides is used in traditional medicine to manage diabetes in the lower eastern part of Kenya. This area is populated mostly by the Kamba community. They take this medicine daily by boiling and consuming the leaves. This species is also used to treat epilepsy, arthritis, typhoid, cough, eye problems, tonsillitis, rheumatism, gonorrhoea, cancer, malaria, dysmenorrhea, sterility, and impotence. In traditional medicine, European and African cultures used the bark of the species in its powdered form, and a teaspoon is used to treat snakebites. The Masai used the root bark for East Coast fever in cattle and diarrhea in their calves. The Haya and Shambala used Rotheca myricoides for dysmenorrhoea and cough, furunculosis and swellings that are associated with debility. In various African communities, the root of the plant is also used for chest pain, colds, gum bleeding indigestion, headaches, and bathing people with convulsions. In West Africa, the plant is used for analgesic and antipyretic purposes. In Asian countries, this species has been brewed as a tea to relieve swelling and pain.
Newsom was sworn in on January 7, 2019. Several recall attempts were launched against Newsom early in his tenure but failed to gain much traction. On February 21, 2020, a recall petition was introduced by Orrin Heatlie, a deputy sheriff in Yolo County. The petition mentioned Newsom's sanctuary state policy and said laws he endorsed favored "foreign nationals, in our country illegally"; said that California had high homelessness, high taxes, and low quality of life; and described other grievances. The California secretary of state approved it for circulation on June 10, 2020. Forcing the gubernatorial recall election required a total of 1,495,709 verified signatures. By August 2020, 55,000 signatures were submitted and verified by the secretary of state, and 890 new valid signatures were submitted by October 2020. The petition was initially given a signature deadline of November 17, 2020, but it was extended to March 17, 2021, after Judge James P. Arguelles ruled that petitioners could have more time because of the pandemic. Newsom's attendance at a party at The French Laundry in November 2020, despite his public health measures; voter anger over lockdowns, job losses, school and business closures; and a $31 billion fraud scandal at the state unemployment agency were credited for the recall's growing support.
== Autoproteolysis == Autoproteolysis takes place in some proteins, whereby the peptide bond is cleaved in a self-catalyzed intramolecular reaction. Unlike zymogens, these autoproteolytic proteins participate in a "single turnover" reaction and do not catalyze further reactions post-cleavage. Examples include cleavage of the Asp-Pro bond in a subset of von Willebrand factor type D (VWD) domains and Neisseria meningitidis FrpC self-processing domain, cleavage of the Asn-Pro bond in Salmonella FlhB protein, Yersinia YscU protein, as well as cleavage of the Gly-Ser bond in a subset of sea urchin sperm protein, enterokinase, and agrin (SEA) domains. In some cases, the autoproteolytic cleavage is promoted by conformational strain of the peptide bond.
Cinnamomum tamala, Indian bay leaf, also known as tejpat, tejapatta, Malabar leaf, Indian bark, Indian cassia, or malabathrum, is a tree in the family Lauraceae that is native to northern India (Assam and the Western Himalayas), Bangladesh, Nepal, Myanmar, Laos, Vietnam, and southwestern China. It can grow up to 20 m (66 ft) tall. Its leaves have a clove-like aroma with a hint of peppery taste; they are used for culinary and medicinal purposes. It is thought to have been one of the major sources of the medicinal plant leaves known in classic and medieval times as malabathrum (or malobathrum).
can be quite complex, there is typically one rate-determining enzymatic step that allows this reaction to be modelled as a single catalytic step with an apparent unimolecular rate constant kcat. If the reaction path proceeds over one or several intermediates, kcat will be a function of several elementary rate constants, whereas in the simplest case of a single elementary reaction (e.g. no intermediates) it will be identical to the elementary unimolecular rate constant k2. The apparent unimolecular rate constant kcat is also called turnover number, and denotes the maximum number of enzymatic reactions catalysed per second. The Michaelis–Menten equation describes how the (initial) reaction rate v0 depends on the position of the substrate-binding equilibrium and the rate constant k2.
Sources: en.wikipedia.org
Trial results generally show a small to moderate average improvement in desire scores relative to placebo. The distribution of responses is wide, and some participants show little measurable change. Group averages should not be read as a prediction for any single person.
Nausea, flushing, headache, and transient blood pressure elevation are the most frequently reported events. These typically appear shortly after dosing and are usually described as mild to moderate in severity. Safety data covering long periods of continuous use remain limited.
A short half-life means the compound clears from circulation within hours, so any effect is tied closely to dosing time. Accumulation between doses is therefore unlikely under the studied schedule. The practical consequence is that timing of administration shapes what observers record.
It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.